Terms: = Colorectal cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Clinical Outcome
11 results:
1. HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.
Jia X; Wang H; Li Z; Yan J; Guo Y; Zhao W; Gao L; Wang B; Jia Y
Mol Med Rep; 2020 Apr; 21(4):1779-1788. PubMed ID: 32319604
[TBL] [Abstract] [Full Text] [Related]
2. DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.
Bigagli E; De Filippo C; Castagnini C; Toti S; Acquadro F; Giudici F; Fazi M; Dolara P; Messerini L; Tonelli F; Luceri C
Cell Oncol (Dordr); 2016 Dec; 39(6):545-558. PubMed ID: 27709558
[TBL] [Abstract] [Full Text] [Related]
3. Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic colorectal cancer.
Yonesaka K; Takegawa N; Satoh T; Ueda H; Yoshida T; Takeda M; Shimizu T; Chiba Y; Okamoto I; Nishio K; Tamura T; Nakagawa K
PLoS One; 2015; 10(11):e0143132. PubMed ID: 26569500
[TBL] [Abstract] [Full Text] [Related]
4. erbb-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G
Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848
[TBL] [Abstract] [Full Text] [Related]
5. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
Giampieri R; Mandolesi A; Abouelkhair KM; Loretelli C; Del Prete M; Faloppi L; Maristella B; Ibrahim EM; Scarpelli M; Cascinu S; Scartozzi M
J Transl Med; 2015 May; 13():140. PubMed ID: 25943333
[TBL] [Abstract] [Full Text] [Related]
6. her3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.
Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
Acta Oncol; 2015 Apr; 54(4):480-6. PubMed ID: 25601452
[TBL] [Abstract] [Full Text] [Related]
7. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients.
Giampieri R; Aprile G; Del Prete M; Faloppi L; Bianconi M; Bonotto M; Fasola G; Cascinu S; Scartozzi M
Curr Drug Targets; 2014; 15(13):1225-30. PubMed ID: 25382208
[TBL] [Abstract] [Full Text] [Related]
8. her3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome.
Lédel F; Hallström M; Ragnhammar P; Öhrling K; Edler D
Eur J Cancer; 2014 Feb; 50(3):656-62. PubMed ID: 24300455
[TBL] [Abstract] [Full Text] [Related]
9. Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.
Scartozzi M; Giampieri R; Loretelli C; Mandolesi A; del Prete M; Biagetti S; Alfonsi S; Faloppi L; Bianconi M; Bittoni A; Bearzi I; Cascinu S
Future Oncol; 2013 Aug; 9(8):1207-14. PubMed ID: 23617461
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract] [Full Text] [Related]
11. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
Scartozzi M; Mandolesi A; Giampieri R; Bittoni A; Pierantoni C; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biscotti T; Biagetti S; Bearzi I; Cascinu S
Oncologist; 2011; 16(1):53-60. PubMed ID: 21212430
[TBL] [Abstract] [Full Text] [Related]
